Skip to content
2000
Volume 15, Issue 8
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Diabetic retinopathy (DR) is a leading cause of blindness in adults at working age. Human diabetic retinopathy is characterized by the basement membrane thick, pericytes loss, microaneurysms formation, retina neovascularization and vitreous hemorrhage. To investigate whether UPP activated ROS/PARP and NF-ΚB inflammatory factor pathways in Diabetic Retinopathy, human retinal endothelial cells (HRECs) and rats with streptozotocin-induced diabetes were used to determine the effect of UPP on ROS generation, cell apoptosis, mitochondrial membrane potential (ΔΨm) and inflammatory factor protein expression, through flow cytometry assay, immunohistochemistry, Real-time PCR, Western blot analysis and ELISA. The levels of ROS and apoptosis and the expressions of UPP (Ub and E3) and inflammatory factor protein were increased in high glucose-induced HRECs and retina of diabetic rats, while ΔΨm was decreased. The UPP inhibitor and UbshRNA could attenuate these effects through inhibiting the pathway of ROS/PARP and the expression of NF-ΚB inflammatory factors, and the increased UPP was a result of high glucose-induced increase of ROS generation and NF-ΚBp65 expression, accompanied with the decrease of ΔΨm. Clinical study showed the overexpression of UPP and detachment of epiretinal membranes in proliferative DR (PDR) patients. It has been indicated that the pathogenic effect of UPP on DR was involved in the increase of ROS generation and NF-ΚB expression, which associated with the ROS/PARP and NF-ΚB inflammatory factor pathways. Our study supports a new insight for further application of UPP inhibitor in DR treatment.

Loading

Article metrics loading...

/content/journals/cmm/10.2174/1566524015666150921110500
2015-09-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/cmm/10.2174/1566524015666150921110500
Loading

  • Article Type:
    Research Article
Keyword(s): Diabetic retinopathy; ERMs; NF-ΚB; PARP; ROS; UPP
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test